#249

COMPLETE

Collector:	Web Link 1 (Web Link)
Started:	Wednesday, September 09, 2026 1:18:21 PM
Last Modified:	Wednesday, September 09, 2026 1:23:34 PM
Time Spent:	00:05:12
IP Address:	98.45.9.253

Page 2: Part 1

Q1

Title of activity

2026 Annual Scientific Meeting

Q2

Date of activity

Oct 17, 2026

Q3

What is your role in the CPD activity? (Select all that apply)

Speaker

Q4

What's your practice type?

Academic Practice

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Respondent skipped this question

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s) (separate with commas)	**Bambusa Therapeutics, Blueprint Medicine, Celldex Therapeutics, Disc Medicine, Galderma, Novartis, Pfizer, Regeneron, Sanofi**
Description of relationship(s)	**advisory boards**

Q8

Funded grants or clinical trials

Name of FOR PROFIT and/or NOT-for-profit organization(s) (separate with commas)	**Galderma, Celldex**
Description of relationship(s)	**clinical trial investigator**

Q9 **Respondent skipped this question**

Patents on a drug, product or device

Q10

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Name of FOR PROFIT and/or NOT-FOR PROFIT organization(s) (separate with commas)	**New Frontier Bio**
Description of relationship(s)	**scientific co-founder (unrelated to topic of talk or my dermatology field of expertise)**

Page 3: Part 2: To be completed by presenters only

Q11 **No**

I intend to use trade names during my presentation.Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

Q12 **No**

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).Note: You must declare all off-label use to the audience during your presentation.

Q13

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

N/A

Q14

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Yes

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15

I confirm that I've completed the EDI Survey linked above

Yes

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Sarina

Q17

Last Name:

Elmariah

Q18

Gender Pronouns - How would you like us to address you?

She/Her

Q19

Please review and check the items below.

I confirm that the above information is accurate and complete.

,

I understand that this information may be publicly available